CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyDNA repair targeted therapy: The past or future of cancer treatment?Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage responseModel-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced CancerA phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.Targeting DNA repair pathways for cancer treatment: what's new?Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer.Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapyTargeting lung cancer through inhibition of checkpoint kinases.Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21.CHK1-driven histone H3.3 serine 31 phosphorylation is important for chromatin maintenance and cell survival in human ALT cancer cells.Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphomaRNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancerMiR-195 suppresses non-small cell lung cancer by targeting CHEK1.Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft modelsInhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.Pcf1, a large subunit of CAF-1, required for maintenance of checkpoint kinase Cds1 activity.The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagyCHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response.Analysis of Protein Phosphorylation and Its Functional Impact on Protein-Protein Interactions via Text Mining of the Scientific Literature.Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironmentDNA replication stress and cancer: cause or cure?An application of CIFAP for predicting the binding affinity of Chk1 inhibitors derived from 2-aminothiazole-4-carboxamide.Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma.Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.Targeting DNA repair and replication stress in the treatment of ovarian cancer.Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells.Cyclin-dependent kinase inhibitor flavopiridol promotes remyelination in a cuprizone induced demyelination model.CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling.Predicting essential genes and synthetic lethality via influence propagation in signaling pathways of cancer cell fates.Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer CellsModification of tumour cell metabolism modulates sensitivity to Chk1 inhibitor-induced DNA damage.Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors.
P2860
Q26745686-824C04D1-5194-4892-9F60-A0481E89FBACQ26768679-29A4CB2F-3F5B-4333-A3CB-908685E4F91AQ27014080-6590379B-531B-4919-B759-4F39317F0D4CQ30838395-47A12CA3-9EA3-46CA-804C-7467BECBDD45Q33431248-E60CFBDB-9BEB-4424-B090-7582EFFA52E1Q33439342-88C96DE5-4D13-46BA-B57D-F83485EFD5D1Q34015040-60FED739-3CDF-4073-9672-B3B77CF406C9Q34028486-960405A5-15D3-4AAD-A6E8-43421F947718Q34654741-B8254E40-BB6A-4732-92E9-0F23F40CD8C8Q35128547-B05D34F0-F82D-4064-BFFD-F1E8D1298C86Q35149603-249B5FE7-8D86-4F4E-B5DC-398707A4993AQ35171587-7EF6845C-509C-4427-807E-5C9328462A9BQ35550255-CBEBB3E4-CF29-4E38-9D1A-7634F353E48DQ35793735-81748478-A588-402B-9A35-A8D601ABDB40Q35832394-42B2DA2D-F3CF-46E3-BD26-A3456834EF4FQ35953034-05803CF0-B048-4518-B888-755DE714D9C3Q36187661-02A0AB44-06DB-46EF-8772-5A9EAB3B3E01Q36546455-5449BB97-DD52-4E9D-B76A-B0DC8C0241D5Q36771796-34C06DC2-EFE1-4500-9F4E-C45C58C80B1DQ36838392-52B6E8EA-29F1-4CAC-A411-1BB16824D0F1Q37515757-A41D2F7C-14D8-4C84-821A-DA97AABD0241Q37744731-7EB70EEF-A71E-4B01-ADAD-07E81E98D0B4Q38379668-CD9C26F4-5D1B-43BB-B4E6-3B84EE502240Q38381392-3F9E86D5-8F83-4E34-9AE1-663FB78AC47EQ38468410-F543970B-3AE7-417E-A246-1D31BA754842Q38652528-60FA3849-7DCE-4A36-A97E-001131CD9568Q38670329-79139620-8DAE-4A7D-B8D8-13FEADDB6350Q38695896-177D3B10-43EE-437D-95E7-2639B46A691FQ38718745-0B037CB1-84F2-4B7F-84E9-B4A47D1E60E7Q38756843-1B951B30-DA4B-4602-8D2A-D7EBE70F41F4Q38901610-6715E361-10BD-4F4E-AFC0-2AF7B378CEE0Q39393235-238F689F-2040-4927-8345-2C6A8E58BC05Q39650689-BDBF5FA9-31DB-44B5-8A65-713724D80B9BQ39987364-64FFC97F-20D6-465D-809C-AEE99775512AQ41352911-F00BD8AD-401D-4E02-A750-668D34D9A051Q41432461-5F26B6C9-EB51-4EED-9145-2DE1508999B6Q41453230-EED68B32-BDFF-4103-9233-DC9B51CAB78EQ41470356-D9C58EDF-8FB4-46D4-AAE1-260E95CA11C2Q41913553-D8ED4554-1354-4CBB-9E64-BA1EE26FE2BBQ42128090-C50AD549-C497-4FF8-BA53-82EFA85460F4
P2860
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
@ast
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
@en
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
@nl
type
label
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
@ast
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
@en
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
@nl
prefLabel
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
@ast
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
@en
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
@nl
P2093
P3181
P1476
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
@en
P2093
A K Bence Lin
R Beckmann
P3181
P356
10.1016/J.PHARMTHERA.2013.10.005
P407
P577
2014-04-01T00:00:00Z